Zyprexa works, but may cause profound sedation, FDA staff says

An FDA official has issued a memo citing reports of excessive sedation in some patients who received a long-acting, injectable form of Zyprexa, Eli Lilly and Co.'s blockbuster schizophrenia drug. The Indianapolis-based drugmaker says the formulation offers advantages that outweigh safety concerns, which it says "are manageable with appropriate labeling and risk-minimization activities."

View Full Article in:

Wall Street Journal (free content), The · Indianapolis Star (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC